A new treatment for retinal vein occlusion (RVO), one of the most common forms of eye disorder in the UK, has been described as "very welcome" by one expert.
According to Professor Peter Littlejohns, clinical and public health director at the National Institute for Health and Clinical Excellence (NICE), the dexamethasone (Ozurdex, Allergan) intravitreal implant can help to change lives.
It works by being injected directly into the eye every six months and was proved to be sufficiently safe by manufacturers prior to approval, the expert noted.
"We are pleased to be able to recommend dexamethasone intravitreal implant for this condition. RVO can be very debilitating and have a very profound effect on everyday life so this draft decision will be welcome news to all those affected," Professor Littlejohns stated.
Meanwhile, diseases of the eye are an excellent target for gene therapy because the ocular environment is readily accessible, relatively easy to monitor and sequestered from the rest of the body, research in the journal Human Gene Therapy recently suggested.
by Emily Tait